Gossamer Bio, Inc.
GOSSGossamer Bio, Inc. in brief
Gossamer Bio, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $65 M on 29 October 2026, which makes it the 20,335th largest listed company in the world and the 3,740th largest in the USA on this site. In the year to December 2025 it had sales of $48 M and a net loss of $170 M. Faheem Hasnain is its chief executive. Its largest product and service lines by sales in 2025 were Revenue from contracts with collaborators (100%). Its shares trade under the symbol GOSS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Gossamer Bio, Inc.
Gossamer Bio is a Clinical Stage Biopharmaceutical company. It is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company estimated annual revenue is currently 6 million USD per year and 118 employees as on 2020 . The headquarters is in USA.
Gossamer Bio, Inc. timeline
- 2018
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 8 February 2019; shares registered for exchange trading on 4 February 2019.
Events of Gossamer Bio, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,991 (Jan 2020) · #2,443 (Jan 2021) · #2,642 (Jan 2022) · #3,782 (Dec 2022) · #4,031 (Jul 2023) · #3,188 (Jan 2024) · #1,900 (Mar 2026) · #3,579 (Aug 2026) · #3,765 (Oct 2026) · #3,744 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.8×
- Price / book
- —
- Free cash flow yield
- -262.1%
- Net margin (TTM)
- -159.5%
- Operating margin
- -352.2%
- Return on equity
- —
- Liabilities / assets
- 171.3%
- Net debt
- $-46M
- Revenue growth
- -57.7%
- R&D / revenue
- 359.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $48M | -57.7% | $-171M | $-170M | -351.5% |
| Dec 2024 | $115M | — | $-60M | $-57M | -49.3% |
| Dec 2023 | — | — | $-184M | $-180M | — |
| Dec 2022 | — | — | $-219M | $-229M | — |
| Dec 2021 | — | — | $-216M | $-234M | — |
| Dec 2020 | — | — | $-234M | $-243M | — |
| Dec 2019 | — | — | $-186M | $-180M | — |
| Dec 2018 | — | — | $-149M | $-147M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-171M | $0M | $-171M | $-0.75 | — |
| Dec 2024 | $-3M | $0M | $-3M | $-0.25 | — |
| Dec 2023 | $-159M | $0M | $-159M | $-1.18 | — |
| Dec 2022 | $-187M | $0M | $-187M | $-2.71 | — |
| Dec 2021 | $-189M | $2M | $-190M | $-3.13 | — |
| Dec 2020 | $-176M | $2M | $-178M | $-3.55 | — |
| Dec 2019 | $-145M | $3M | $-148M | $-3.29 | — |
| Dec 2018 | $-51M | $3M | $-55M | $-22.59 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $38M (+189.2% on a year earlier), net income $-48M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 20268-KCurrent reportResults of operations
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Oct 28, 20268-KCurrent reportShareholder vote
- Sep 28, 20268-KCurrent reportOther events
- Sep 23, 20268-KCurrent reportOther events
- Sep 16, 2026DEF 14AProxy statement
- Sep 16, 20268-KCurrent reportDirectors or officers changed
- Sep 11, 20268-KCurrent reportBylaws amended · Other events
- Sep 9, 20268-KCurrent reportOther events
- Sep 3, 20268-KCurrent reportBylaws amended
- Aug 26, 20268-KCurrent reportBylaws amended
- Aug 21, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Bylaws amended · Regulation FD disclosure
Official filings of Gossamer Bio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $48 M
- Operating income
- $-171 M
- Net income
- $-170 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $172 M
- Total liabilities
- $295 M
- Total equity
- $-123 M
As of December-2025
Top 73 institutional investors in Gossamer Bio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | 683 Capital Management, LLC | 489,985 | New | 8.01% | $6 M | Nov 16, 2026 |
| 2 | Opaleye Management Inc. | 426,989 | New | 6.98% | $5 M | Nov 16, 2026 |
| 3 | Context Capital Management, LLC | 361,830 | New | 5.92% | $4 M | Nov 4, 2026 |
| 4 | D. E. Shaw & Co., Inc. | 304,748 | New | 4.98% | $4 M | Nov 16, 2026 |
| 5 | FMR LLC | 290,939 | New | 4.76% | $3 M | Nov 10, 2026 |
| 6 | SummitTX Capital, L.P. | 182,111 | New | 2.98% | $2 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 160,648 | New | 2.63% | $2 M | Nov 13, 2026 |
| 8 | Kalehua Capital Management LLC | 139,366 | New | 2.28% | $2 M | Nov 13, 2026 |
| 9 | BlackRock, Inc. | 107,423 | New | 1.76% | $1 M | Nov 13, 2026 |
| 10 | ARCH Venture Management, LLC | 100,698 | New | 1.65% | $1 M | Nov 16, 2026 |
| 11 | Marshall Wace, LLP | 99,503 | New | 1.63% | $1 M | Nov 13, 2026 |
| 12 | Samsara Biocapital, LLC | 87,956 | New | 1.44% | $1 M | Nov 16, 2026 |
| 13 | Corient Private Wealth LP | 83,160 | New | 1.36% | $1 M | Nov 16, 2026 |
| 14 | Highbridge Capital Management LLC | 75,697 | New | 1.24% | $1 M | Nov 16, 2026 |
| 15 | Geode Capital Management, LLC | 70,318 | New | 1.15% | $1 M | Nov 6, 2026 |
| 16 | Siren, L.L.C. | 65,112 | New | 1.06% | $1 M | Nov 12, 2026 |
| 17 | Squarepoint Ops LLC | 64,853 | New | 1.06% | $1 M | Nov 9, 2026 |
| 18 | Stonepine Capital Management, LLC | 63,039 | New | 1.03% | $1 M | Nov 13, 2026 |
| 19 | Hhlr Advisors, LTD. | 62,175 | New | 1.02% | $1 M | Nov 16, 2026 |
| 20 | Bank Of America Corp /de/ | 60,383 | New | 0.99% | $1 M | Nov 16, 2026 |
| 21 | Balyasny Asset Management L.P. | 45,540 | New | 0.74% | $1 M | Nov 16, 2026 |
| 22 | Arrowstreet Capital, Limited Partnership | 41,604 | New | 0.68% | $0 M | Nov 13, 2026 |
| 23 | Jane Street Group, LLC | 37,652 | New | 0.62% | $0 M | Nov 12, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 35,683 | New | 0.58% | $0 M | Nov 13, 2026 |
| 25 | Gsa Capital Partners LLP | 32,806 | New | 0.54% | $0 M | Nov 16, 2026 |
Show all 73: investors 26 to 73
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | State Street Corp | 32,175 | New | 0.53% | $0 M | Nov 12, 2026 |
| 27 | MB Generational Wealth, LLC | 27,904 | New | 0.46% | $0 M | Nov 9, 2026 |
| 28 | Renaissance Technologies LLC | 27,725 | New | 0.45% | $0 M | Nov 12, 2026 |
| 29 | Monaco Asset Management SAM | 25,461 | New | 0.42% | $0 M | Nov 9, 2026 |
| 30 | Empery Asset Management, LP | 24,954 | New | 0.41% | $0 M | Nov 16, 2026 |
| 31 | Goldman Sachs Group Inc | 24,826 | New | 0.41% | $0 M | Nov 16, 2026 |
| 32 | Ishara Investments LP | 24,000 | New | 0.39% | $0 M | Nov 16, 2026 |
| 33 | Luminus Management LLC | 19,611 | New | 0.32% | $0 M | Nov 16, 2026 |
| 34 | Ensign Peak Advisors, Inc | 16,751 | New | 0.27% | $0 M | Nov 12, 2026 |
| 35 | Vanguard Portfolio Management LLC | 16,500 | New | 0.27% | $0 M | Nov 13, 2026 |
| 36 | UBS Group AG | 14,984 | New | 0.24% | $0 M | Nov 10, 2026 |
| 37 | Hennion & Walsh Asset Management, Inc. | 14,203 | New | 0.23% | $0 M | Oct 13, 2026 |
| 38 | AQR Capital Management LLC | 13,974 | New | 0.23% | $0 M | Nov 16, 2026 |
| 39 | Northern Trust Corp | 13,940 | New | 0.23% | $0 M | Nov 16, 2026 |
| 40 | Invesco Ltd. | 13,054 | New | 0.21% | $0 M | Nov 12, 2026 |
| 41 | Smith, Moore & Co. | 11,250 | New | 0.18% | $0 M | Nov 12, 2026 |
| 42 | Morgan Stanley | 6,763 | New | 0.11% | $0 M | Nov 13, 2026 |
| 43 | Citigroup Inc | 5,250 | New | 0.09% | $0 M | Nov 4, 2026 |
| 44 | Acadian Asset Management LLC | 4,468 | New | 0.07% | $0 M | Nov 9, 2026 |
| 45 | Quarry LP | 3,000 | New | 0.05% | $0 M | Nov 16, 2026 |
| 46 | Deutsche Bank AG\ | 1,831 | New | 0.03% | $0 M | Nov 6, 2026 |
| 47 | Osaic Holdings, Inc. | 1,626 | New | 0.03% | $0 M | Nov 12, 2026 |
| 48 | Group One Trading LLC | 1,421 | New | 0.02% | $0 M | Nov 10, 2026 |
| 49 | Tower Research Capital LLC (TRC) | 1,337 | New | 0.02% | $0 M | Nov 16, 2026 |
| 50 | Rockefeller Capital Management L.P. | 1,320 | New | 0.02% | $0 M | Nov 13, 2026 |
| 51 | China Universal Asset Management Co., Ltd. | 1,115 | New | 0.02% | $0 M | Oct 28, 2026 |
| 52 | Vanguard Global Advisers, LLC | 996 | New | 0.02% | $0 M | Nov 13, 2026 |
| 53 | Farther Finance Advisors, LLC | 641 | New | 0.01% | $0 M | Oct 8, 2026 |
| 54 | Federation des caisses Desjardins du Quebec | 609 | New | 0.01% | $0 M | Nov 16, 2026 |
| 55 | Russell Investments Group, Ltd. | 455 | New | 0.01% | $0 M | Nov 6, 2026 |
| 56 | BNP Paribas Financial Markets | 349 | New | 0.01% | $0 M | Nov 12, 2026 |
| 57 | Royal Bank Of Canada | 318 | New | 0.01% | $0 M | Nov 16, 2026 |
| 58 | Mirae Asset Global Investments Co., Ltd. | 312 | New | 0.01% | $0 M | Oct 29, 2026 |
| 59 | Clearstead Advisors, LLC | 294 | New | 0.00% | $0 M | Nov 6, 2026 |
| 60 | Jpmorgan Chase & Co | 287 | New | 0.00% | $0 M | Nov 12, 2026 |
| 61 | Rialto Wealth Management, LLC | 256 | New | 0.00% | $0 M | Nov 16, 2026 |
| 62 | Robinhood Markets, Inc. | 107 | — | 0.00% | $0 M | Nov 18, 2026 |
| 63 | BFC Planning, Inc. | 78 | New | 0.00% | $0 M | Nov 13, 2026 |
| 64 | Jones Financial Companies Lllp | 55 | New | 0.00% | $0 M | Nov 13, 2026 |
| 65 | GAMMA Investing LLC | 44 | New | 0.00% | $0 M | Oct 8, 2026 |
| 66 | Essential Partners LLC | 32 | New | 0.00% | $0 M | Oct 14, 2026 |
| 67 | Planning Strategies Inc. | 32 | New | 0.00% | $0 M | Oct 2, 2026 |
| 68 | EverSource Wealth Advisors, LLC | 31 | New | 0.00% | $0 M | Nov 4, 2026 |
| 69 | Parallel Advisors, LLC | 26 | New | 0.00% | $0 M | Nov 3, 2026 |
| 70 | Nisa Investment Advisors, LLC | 24 | New | 0.00% | $0 M | Oct 20, 2026 |
| 71 | Arax Advisory Partners | 17 | New | 0.00% | $0 M | Nov 12, 2026 |
| 72 | Wells Fargo & Company/mn | 12 | New | 0.00% | $0 M | Nov 16, 2026 |
| 73 | SBI Securities Co., Ltd. | 4 | New | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding Gossamer Bio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 6.91 M | $1 M | 1.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 2.24 M | $0 M | 0.51% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 1.15 M | $0 M | 0.26% | <0.01% | +6.1% | May 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 1.50 M | $0 M | 0.34% | <0.01% | −0.6% | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 986,826 | $0 M | 0.22% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 977,030 | $0 M | 0.22% | <0.01% | +2.8% | May 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 541,950 | $0 M | 0.12% | <0.01% | −0.9% | May 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 556,395 | $0 M | 0.13% | <0.01% | +17% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 381,135 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 365,199 | $0 M | 0.08% | <0.01% | no change | May 29, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 300,421 | $0 M | 0.07% | <0.01% | +1.6% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 294,007 | $0 M | 0.07% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 267,245 | $0 M | 0.06% | <0.01% | +1046% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 180,256 | $0 M | 0.04% | <0.01% | +3.1% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 149,688 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 154,416 | $0 M | 0.03% | <0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 145,404 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 107,368 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 73,097 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 99,976 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC | 57,126 | $0 M | 0.01% | <0.01% | +86% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 74,746 | $0 M | 0.02% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION | 47,330 | $0 M | 0.01% | <0.01% | +108% | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 60,195 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 59,400 | $0 M | 0.01% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 50,820 | $0 M | 0.01% | <0.01% | −22% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 28,300 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 35,839 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 36,524 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 31,955 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 30,015 | $0 M | <0.01% | <0.01% | −18% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 16,683 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 21,834 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 13,387 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 9,043 | $0 M | <0.01% | <0.01% | +8.7% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 7,222 | $0 M | <0.01% | <0.01% | −5.1% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 7,146 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 10,553 | $0 M | <0.01% | <0.01% | −35% | Jun 30, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 7,072 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 9,057 | $0 M | <0.01% | <0.01% | −7.6% | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 6,117 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 4,901 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 5,067 | $0 M | <0.01% | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 1,290 | $0 M | <0.01% | <0.01% | +7.4% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 44 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Gossamer Bio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Waage ChristianEVP, Tech Ops and Admin | Grant or award | +84,500 | — | — | 814,061 | Form 4 |
| filed | Faheem HasnainPresident & CEO, Director | Grant or award | +280,000 | — | — | 837,793 | Form 4 |
| filed | Caryn PetersonEVP, Regulatory Affairs | Grant or award | +84,500 | — | — | 259,333 | Form 4 |
| filed | Bryan GiraudoCOO/CFO | Grant or award | +115,750 | — | — | 389,737 | Form 4 |
| filed | Richard ArandaChief Medical Officer | Grant or award | +93,750 | — | — | 463,106 | Form 4 |
| filed | Robert Paul Smith Jr.Chief Commercial Officer | Grant or award | +93,750 | — | — | 260,898 | Form 4 |
| filed | Waage ChristianEVP, Tech Ops and Admin | Grant or award | +125,000 | — | — | 710,934 | Form 4 |
| filed | Robert Paul Smith Jr.Chief Commercial Officer | Grant or award | +162,500 | — | — | 162,500 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Gossamer Bio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-80 reverse split ; 1-for-454.55 reverse split
Trading halts
- 2026-09-10 23:50 UTC, code T3, resumed 13:00 UTC
- 2026-02-23 12:58 UTC, code T3, resumed 13:30 UTC
Fails to deliver
- : 7,524 shares at $10.69
- : 6,808 shares at $9.77
- : 678 shares at $9.15
- : 9,232 shares at $9.61
- : 3,807 shares at $9.46
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Gossamer Bio, Inc. scorecard#
Passes 4 of the 14 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median0.8×Price to sales 0.8× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 3
- ✗Revenue grew in the newest year-57.7%Revenue down 57.7% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.75 vs -0.25Diluted EPS -0.75 in fiscal 2025 against -0.25 the year before (report's currency).
- ✓Net income higher than five years earlier-$170 M-$170 M in fiscal 2025 against -$243 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$170 MNet income -$170 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-352.2%-352.2% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.64 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-13.83Z-score -13.83 (distress zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.0%Diluted shares up 1.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Gossamer Bio, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -352.2% | -60.5% | |
| Net margin | -351.5% | -68.9% | |
| Revenue growth | -57.7% | 15.8% | |
| Free cash flow margin | -353.5% | -61.5% |
1of 7on the Piotroski tests of financial strength
- Revenue fell 57.7% against the year before.
- Net loss of $170 million, the 9th loss-making year in a row.
- Free cash flow was negative: -$171 million.
- Shareholders' equity is negative: -$123 million.
Gossamer Bio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 48−57.7%100% | 115—100% | 0—— | 0—— | — | — | — | — | — | |
| Research and development | 174+25.7%359% | 138+2.4%121% | 135−20.8%— | 171+0.4%— | 170+5.9%— | 161+12.2%— | 143+159%— | 55+6105%— | 0.9—— | |
| General and administrative | 38+4.1%77.6% | 36−6.0%31.5% | 38−19.2%— | 48+4.0%— | 46−7.9%— | 50+27.1%— | 39−11.2%— | 44+16713%— | 0.3—— | |
| Operating expenses | 219+25.5%452% | 175−5.0%152% | 184−15.9%— | 219+1.1%— | 216−7.6%— | 234+25.7%— | 186+24.9%— | 149+2139%— | 6.7—— | |
| Operating income | −171—−352% | −60—−52.2% | −184—— | −219—— | −216—— | −234—— | −186—— | −149—— | −6.7—— | |
| Interest and finance income | 2.0+10.7%4.1% | 1.8−10.9%1.6% | 2.0+26.2%— | 1.6+108%— | 0.8−77.9%— | 3.4−38.1%— | 5.6+223%— | 1.7—— | — | |
| Interest expense and finance costs | 11−4.6%22.7% | 12−14.8%10.0% | 14−2.7%— | 14−28.6%— | 19+53.5%— | 13+554%— | 1.9+16050%— | 0.0—— | — | |
| Other non-operating income (expense) | 0.3−93.7%0.6% | 4.3+8.7%3.7% | 3.9—— | −11r1.5—— | −18r0.8—— | −0.2−103%— | 5.8+188%— | 2.0—— | −0.1—— | |
| Income before tax | −170—−352% | −56—−48.5% | −180r−180—— | −229r−229—— | −234—— | −243—— | −180r180—— | −147r147−2271%— | 6.8—— | |
| Income tax | −0.1−110%−0.2% | 0.9—0.8% | 0—— | 0—— | — | — | 0—— | 0—— | 0—— | |
| Net income including minority interests | −170—−351% | −57—−49.3% | −180—— | −229—— | −234—— | −243—— | −180—— | −147—— | −6.8—— | |
| Net income attributable to shareholders | −170—−351% | −57—−49.3% | −180—— | −229—— | −234—— | −243—— | −180—— | −147—— | −6.8—— | |
| Earnings per share, basic | -0.75—— | -0.25—— | -1.18—— | -2.71—— | -3.13—— | -3.55—— | -3.29—— | -22.59—— | -0.74—— | |
| Earnings per share, diluted | -0.75—— | -0.25—— | -1.18—— | -2.71—— | -3.13—— | -3.55—— | -3.29—— | -22.59—— | -0.74—— | |
| Shares, weighted average (basic) | 229+1.0%— | 226+48.2%— | 153+80.5%— | 85+13.0%— | 75+9.2%— | 69+25.2%— | 55—— | — | — | |
| Shares, weighted average (diluted) | 229+1.0%— | 226+48.2%— | 153+80.5%— | 85+13.0%— | 75+9.2%— | 69+25.2%— | 55+742%— | 6.5−29.0%— | 9.2—— | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 38−18.1%21.9% | 46+43.5%14.6% | 32−71.3%10.3% | 112−38.9%41.1% | 183−62.3%53.4% | 486+260%90.1% | 135r135+28.3%31.7% | 105+33303%43.9% | 0.3—— | |
| Short-term investments | 99−60.1%57.6% | 248−6.0%78.8% | 264+83.9%84.7% | 144+1.3%52.7% | 142+434%41.3% | 27−90.0%4.9% | 267+116%62.5% | 123—51.6% | — | |
| Receivables | 12+129%7.1% | 5.3—1.7% | 0—0.0% | — | — | — | — | — | — | |
| Other current assets | 18+84.3%10.7% | 10−0.6%3.2% | 10+62.8%3.2% | 6.2−4.6%2.3% | 6.5−28.8%1.9% | 9.1+21.9%1.7% | 7.5+142%1.8% | 3.1—1.3% | — | |
| Current assets | 168−45.9%97.3% | 310+1.1%98.3% | 307+17.0%98.3% | 262−21.1%96.1% | 332−36.5%96.5% | 522+27.6%96.8% | 409+76.5%95.9% | 232—96.9% | — | |
| Property, plant and equipment | 0.1+540%0.0% | 0.0−99.4%0.0% | 1.6−58.6%0.5% | 4.0−25.2%1.5% | 5.3−3.9%1.5% | 5.5+2.0%1.0% | 5.4+69.9%1.3% | 3.2—1.3% | — | |
| Right-of-use (leased) assets | 4.1−19.1%2.4% | 5.1+63.2%1.6% | 3.1−47.0%1.0% | 5.9+7.9%2.2% | 5.5−48.1%1.6% | 11+2.4%2.0% | 10—2.4% | — | — | |
| Total assets | 172−45.4%100% | 315+1.1%100% | 312+14.5%100% | 272−20.7%100% | 344−36.3%100% | 539+26.4%100% | 427+78.2%100% | 239—100% | — | |
| Accounts payable | 6.0+157%3.5% | 2.3−58.0%0.7% | 5.5+279%1.8% | 1.5−55.0%0.5% | 3.2−56.8%0.9% | 7.5+685%1.4% | 1.0−56.2%0.2% | 2.2—0.9% | — | |
| Debt due within a year | — | 0−100%0.0% | 120.0%3.7% | 12—4.3% | 0—0.0% | — | — | — | — | |
| Current liabilities | 63+40.9%36.8% | 45−12.8%14.3% | 52+4.8%16.5% | 49+23.5%18.1% | 40+3.1%11.6% | 39+4.7%7.2% | 37+81.0%8.7% | 20—8.5% | — | |
| Long-term debt | — | 0−100%0.0% | 0.8−93.2%0.3% | 12−58.8%4.4% | 29+1.2%8.5% | 29+1.0%5.3% | 28—6.7% | — | — | |
| Lease liabilities (non-current) | 3.5−21.3%2.0% | 4.4+2954%1.4% | 0.1−95.8%0.0% | 3.4+7.1%1.3% | 3.2−58.3%0.9% | 7.7−11.7%1.4% | 8.7—2.0% | — | — | |
| Total liabilities | 295+3.2%171% | 286+14.7%90.6% | 249−4.3%79.9% | 260+17.2%95.6% | 222+1.6%64.7% | 219+195%40.6% | 74+251%17.4% | 21—8.8% | — | |
| Retained earnings | −1,439—−835% | −1,269—−402% | −1,212—−389% | −1,032—−379% | −812—−236% | −578—−107% | −334—−78.3% | −154—−64.3% | — | |
| Shareholders' equity | −123−516%−71.3% | 29−53.0%9.4% | 63+420%20.1% | 12−90.1%4.4% | 121−62.1%35.3% | 321−9.0%59.4% | 352—82.6% | −120—−50.2% | −6.9—— | |
| Total liabilities and equity | 172−45.4%100% | 315+1.1%100% | 312+14.5%100% | 272−20.7%100% | 344−36.3%100% | 539+26.4%100% | 427+78.2%100% | 239—100% | — | |
| Shares outstanding | 2.9r234−98.7%— | 227+0.5%— | 225+139%— | 94+24.6%— | 76+2.5%— | 74+19.9%— | 62+666%— | 8.1—— | — | |
| Cash-flow statement | ||||||||||
| Depreciation and amortization | 0.0−97.1%0.0% | 0.8−48.2%0.7% | 1.6−12.3%— | 1.8+5.3%— | 1.7+23.5%— | 1.4+53.7%— | 0.9+209%— | 0.3—— | — | |
| Share-based compensation | 11−48.8%21.8% | 21−27.7%18.0% | 29−33.0%— | 43+32.9%— | 32−17.4%— | 39+86.1%— | 21−32.7%— | 31+96609%— | 0.0—— | |
| Cash from operating activities | −171—−353% | −3.5—−3.0% | −159—— | −187—— | −189—— | −176—— | −145—— | −51—— | −5.7—— | |
| Capital expenditure | −0.1—−0.2% | 0—0.0% | 0—— | −0.4—— | −1.5—— | −1.5—— | −3.0—— | −3.5—— | — | |
| Cash from investing activities | 156+439%323% | 29—25.3% | −111—— | −1.0—— | −117−155%— | 215—— | −147—— | −145—— | — | |
| Debt issued | — | — | — | — | — | — | 28—— | — | — | |
| Debt repaid | 0—0.0% | −13—−11.0% | −12—— | −5.8—— | 0—— | 0—— | — | — | — | |
| Shares issued | — | — | — | 0—— | 0−100%— | 117−59.8%— | 291—— | 0—— | — | |
| Cash from financing activities | 6.4—13.3% | −11−106%−10.0% | 190+62.4%— | 117+3417%— | 3.3−98.9%— | 313−2.8%— | 322+6.9%— | 301+4914%— | 6.0—— | |
| Change in cash | −8.3−160%−17.2% | 14—12.2% | −80—— | −71—— | −303−186%— | 352+1085%— | 30r30−71.8%— | 105+41117%— | 0.3—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 78+78.0%100% | 38+189%100% | 9.2−19.6%100% | 17+71.5%100% | 14*+47.1%100% | 13+40.2%100% | 11−88.0%100% | 9.9—100% | 9.4*—100% | 9.5—100% | 96—100% | 0—— | 0*—— | |
| Research and development | 137−14.9%175% | 19−58.7%49.0% | 26−36.5%286% | 43+13.2%254% | 49*+35.5%355% | 46+30.5%343% | 42+18.5%362% | 38+17.4%385% | 36*+20.5%385% | 35—368% | 35—36.6% | 32—— | 30*—— | |
| General and administrative | 48+33.4%61.4% | 9.6+2.6%25.1% | 8.9+2.5%96.3% | 19+117%111% | 11*+16.1%79.0% | 9.4+10.4%70.6% | 8.7+0.1%75.5% | 8.7−9.5%87.6% | 9.4*+3.7%100% | 8.5—89.7% | 8.7—9.0% | 9.6—— | 9.1*—— | |
| Operating expenses | 188−8.1%240% | 31−49.9%81.3% | 35−29.7%382% | 62+32.4%365% | 60*+31.5%434% | 62+43.8%469% | 50+14.9%437% | 47+11.3%472% | 46*−7.2%485% | 43—458% | 44—45.7% | 42—— | 49*—— | |
| Operating income | −110—−140% | 7.2—18.7% | −26—−282% | −45—−265% | −46*—−334% | −49—−369% | −39−174%−337% | −37—−372% | −36*—−385% | −34—−358% | 52—54.3% | −42—— | −49*—— | |
| Interest and finance income | 1.5—1.9% | 0.4−41.8%1.0% | 0.3−50.6%2.9% | 0.4+20.4%2.1% | 0.4*—3.2% | 0.7+59.8%5.2% | 0.5−69.0%4.7% | 0.3−14.5%3.0% | — | 0.4—4.5% | 1.7—1.8% | 0.3—— | 0.3*—— | |
| Interest expense and finance costs | 11−2.7%13.6% | 2.5−10.3%6.4% | 2.7−1.4%29.3% | 2.8+0.3%16.2% | 2.8*+0.5%19.9% | 2.7+0.5%20.7% | 2.7−5.9%23.9% | 2.7−12.2%27.8% | 2.7*−15.5%29.2% | 2.7—28.8% | 2.9—3.0% | 3.1—— | 3.2*—— | |
| Other non-operating income (expense) | −15−785%−19.6% | −55−6289%−144% | 43+8635%465% | −1.8−1145%−10.6% | −1.3*−287%−9.3% | 0.9−55.0%6.7% | 0.5−68.9%4.3% | 0.2+455%1.7% | 0.7*−21.6%7.3% | 2.0—20.9% | 1.6—1.6% | 0.0—— | 0.9*—— | |
| Income before tax | — | — | — | — | −47*—−343% | −48—−363% | −38−171%−333% | — | −35*—−378% | −32—−337% | 54—56.0% | — | −48r−48*—— | |
| Income tax | — | — | — | — | −0.1*—−0.6% | 0—0.0% | 0−100%0.0% | — | −2.4*—−25.7% | −1.1—−11.9% | 4.4—4.6% | — | 0*—— | |
| Net income including minority interests | −125—−159% | −48*—−125% | 17*—183% | −47—−275% | −47*—−342% | −48*—−363% | −38*−178%−333% | −37—−370% | −33*—−352% | −31*—−325% | 49*—51.4% | −42—— | −48*—— | |
| Net income attributable to shareholders | −125—−159% | −48—−125% | 17—183% | −47—−275% | −47*—−342% | −48—−363% | −38−178%−333% | −37—−370% | −33*—−352% | −31—−325% | 49—51.4% | −42—— | −48*—— | |
| Earnings per share, basic | — | -7.36—— | 0.05—— | -0.20—— | — | -16.92r-0.21—— | -0.17−177%— | -0.16—— | — | -0.14—— | 0.22—— | -0.19—— | — | |
| Earnings per share, diluted | — | -7.36—— | -0.08—— | -0.20—— | — | -16.92r-0.21—— | -0.17−177%— | -0.16—— | — | -0.14—— | 0.22—— | -0.19—— | — | |
| Shares, weighted average (basic) | 6.5+129%— | 6.5+129%— | 320+40.8%— | 234+3.2%— | — | 2.8r228−98.7%— | 227+0.5%— | 227+0.5%— | — | 226—— | 226—— | 226—— | — | |
| Shares, weighted average (diluted) | 6.5+129%— | 6.5+129%— | 329+44.7%— | 234+3.2%— | — | 2.8r228−98.7%— | 227−4.7%— | 227+0.5%— | — | 226—— | 239—— | 226—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 51—79.6% | 51+473%79.6% | 41+56.4%53.5% | 41+41.4%31.8% | 38−18.1%21.9% | 8.9−68.6%4.3% | 26−69.7%10.9% | 29−25.3%10.3% | 46+43.5%14.6% | 28—8.1% | 87—23.3% | 39—15.0% | 32—10.3% | |
| Short-term investments | 0—0.0% | 0−100%0.0% | 16−91.5%20.7% | 58−74.6%45.1% | 99−60.1%57.6% | 171−42.6%82.0% | 187−30.3%77.5% | 229+11.4%81.6% | 248−6.0%78.8% | 299—85.1% | 268—71.7% | 206—79.2% | 264—84.7% | |
| Receivables | 0—0.0% | 0−100%0.0% | 6.1−19.4%7.9% | 9.3+40.5%7.2% | 12+129%7.1% | 9.2+40.3%4.4% | 7.6+109%3.1% | 6.6—2.3% | 5.3—1.7% | 6.6—1.9% | 3.6—1.0% | — | 0—0.0% | |
| Other current assets | 9.2—14.4% | 9.2−36.4%14.4% | 9.6−37.7%12.5% | 16+46.6%12.5% | 18+84.3%10.7% | 15+36.4%7.0% | 15+20.5%6.4% | 11+0.8%3.9% | 10−0.6%3.2% | 11—3.0% | 13—3.4% | 11—4.2% | 10—3.2% | |
| Current assets | 60—93.9% | 60−70.4%93.9% | 73−69.2%94.6% | 125−54.8%96.6% | 168−45.9%97.3% | 204−40.7%97.7% | 236−36.4%97.9% | 275+7.9%98.2% | 310+1.1%98.3% | 344—98.1% | 371—99.3% | 255—98.4% | 307—98.3% | |
| Property, plant and equipment | 0.1—0.1% | 0.1−27.1%0.1% | 0.1−27.6%0.1% | 0.1+103%0.0% | 0.1+540%0.0% | 0.1−76.8%0.0% | 0.1−90.8%0.0% | 0.0−97.3%0.0% | 0.0−99.4%0.0% | 0.3—0.1% | 0.8—0.2% | 1.1—0.4% | 1.6—0.5% | |
| Right-of-use (leased) assets | 3.4—5.3% | 3.4−21.1%5.3% | 3.7−19.9%4.8% | 3.9−18.2%3.0% | 4.1−19.1%2.4% | 4.4−27.7%2.1% | 4.6+175%1.9% | 4.8+98.6%1.7% | 5.1+63.2%1.6% | 6.0—1.7% | 1.7—0.4% | 2.4—0.9% | 3.1—1.0% | |
| Total assets | 64—100% | 64−69.2%100% | 77−68.1%100% | 129−54.1%100% | 172−45.4%100% | 209−40.5%100% | 241−35.5%100% | 281+8.2%100% | 315+1.1%100% | 351—100% | 373—100% | 259—100% | 312—100% | |
| Accounts payable | 1.5—2.3% | 1.5+31.7%2.3% | 6.0+217%7.7% | 11+219%8.4% | 6.0+157%3.5% | 1.1−63.5%0.5% | 1.9+87.6%0.8% | 3.4+27.4%1.2% | 2.3−58.0%0.7% | 3.1—0.9% | 1.0—0.3% | 2.7—1.0% | 5.5—1.8% | |
| Debt due within a year | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 9.6—3.7% | 12—3.7% | |
| Current liabilities | 100—155% | 100+60.9%155% | 138+157%179% | 57+17.2%43.8% | 63+40.9%36.8% | 62+21.6%29.7% | 54+18.6%22.2% | 48+34.6%17.2% | 45−12.8%14.3% | 51—14.6% | 45—12.1% | 36—13.8% | 52—16.5% | |
| Long-term debt | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0.8—0.3% | |
| Lease liabilities (non-current) | 2.7—4.2% | 2.7−27.2%4.2% | 3.0−24.8%3.8% | 3.2−22.9%2.5% | 3.5−21.3%2.0% | 3.7−19.4%1.8% | 3.9—1.6% | 4.2—1.5% | 4.4+2954%1.4% | 4.6—1.3% | 0—0.0% | 0—0.0% | 0.1—0.0% | |
| Total liabilities | 187—291% | 187−35.7%291% | 171−40.5%222% | 290+1.2%225% | 295+3.2%171% | 291−1.9%139% | 287−1.7%119% | 287+23.3%102% | 286+14.7%90.6% | 297—84.6% | 292—78.2% | 233—89.7% | 249—79.9% | |
| Retained earnings | −1,517—−2358% | −1,517—−2358% | −1,469—−1911% | −1,486—−1153% | −1,439—−835% | −1,392—−666% | −1,343—−558% | −1,305—−465% | −1,269—−402% | −1,236—−352% | −1,205—−323% | −1,254—−483% | −1,212—−389% | |
| Shareholders' equity | −123—−191% | −123—−191% | −94—−122% | −161—−125% | −123−516%−71.3% | −82−252%−39.4% | −46−157%−19.1% | −6.3−123%−2.2% | 29−53.0%9.4% | 54—15.4% | 82—21.8% | 27—10.3% | 63—20.1% | |
| Total liabilities and equity | 64—100% | 64−69.2%100% | 77−68.1%100% | 129−54.1%100% | 172−45.4%100% | 209−40.5%100% | 241−35.5%100% | 281+8.2%100% | 315+1.1%100% | 351—100% | 373—100% | 259—100% | 312—100% | |
| Shares outstanding | 6.1—— | 6.1−97.4%— | 489+115%— | 235+3.3%— | 2.9r234−98.7%— | 231+2.1%— | 227+0.5%— | 227+0.4%— | 227+0.5%— | 227—— | 226—— | 226—— | 225—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | 0.0−16.7%0.0% | 0.0*−94.4%0.0% | 0.0*−97.0%0.0% | 0.0*−98.0%0.1% | 0.0−97.7%0.1% | 0.1*−63.0%1.2% | 0.2—2.1% | 0.3—0.3% | 0.3—— | 0.3*—— | |
| Share-based compensation | 15+22.5%19.7% | 3.8+42.2%9.9% | 2.5−4.8%26.7% | 6.3+162%37.2% | 2.9*−41.6%21.0% | 2.7−44.9%20.1% | 2.6−48.3%22.5% | 2.4−58.6%24.3% | 5.0*−17.7%52.9% | 4.8—51.1% | 5.0—5.2% | 5.8—— | 6.0*—— | |
| Cash from operating activities | −156—−199% | −30*—−77.0% | −39*—−427% | −39—−228% | −48*—−350% | −36*—−272% | −47*−140%−410% | −40—−402% | −35*—−378% | −32*—−338% | 116*—121% | −52—— | −33*—— | |
| Capital expenditure | 0—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | −0.1*—−0.5% | −0.0—−0.3% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—— | 0*—— | |
| Cash from investing activities | 173+27.1%221% | 16*−6.5%41.4% | 43*−3.2%462% | 42+88.6%245% | 73*+37.5%530% | 17*—128% | 44*—384% | 22−64.2%223% | 53*—567% | −27*—−282% | −59*—−61.7% | 62—— | −14*—— | |
| Debt repaid | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | −9.7*—−10.1% | −2.9—— | −2.9*—— | |
| Cash from financing activities | 25+914%31.9% | 24*+1167%61.7% | −3.1*−3445%−34.0% | 0.5+1.6%3.0% | 4.0*—28.7% | 1.9*+566%14.1% | 0.1*—0.8% | 0.5—5.1% | 0*—0.0% | 0.3*—3.0% | −9.2*—−9.6% | −2.6—— | −2.9*—— | |
| Change in cash | 42—53.9% | 10*—26.1% | 0.1*—1.3% | 3.3—19.4% | 29*+63.5%209% | −17*—−131% | −2.7*−106%−23.6% | −17−352%−172% | 18*—188% | −58*—−616% | 48*—50.1% | 6.8—— | −51*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Gossamer Bio, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Revenue from contracts with collaborators$48 M100%+102%
Business segments
- Reporting$48 M100%-58%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Gossamer Bio, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office2 subsidiaries | — |
| 🇮🇪 Ireland | 2 subsidiaries | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Gossamer Bio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 4 · Material agreement 4 · Agreement ended 2 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 5 · Shareholder vote 4 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement endedResults announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementAgreement endedNew debtUnregistered share sale | 8-K | |
| Directors and officersMaterial agreementResults announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $25 M | Private placement after listing | $10 to $50 million | 38 | options | SEC |
| Jul 2023 | $212 M | Private placement after listing | $50 to $250 million | 70 | equity, options | SEC |
| Jul 2022 | $120 M | Private placement after listing | $50 to $250 million | 23 | equity | SEC |
| Jul 2018 | $230 M | No. 2 | $50 to $250 million | 67 | equity | SEC |
| Jan 2018 | $70 M | No. 1 | $50 to $250 million | 3 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Gossamer Bio, Inc.#
$10 K spent on lobbying the US Congress and federal agencies in 2026, most often on health issues.
- Health Issues1 report
Lobbying firms hired in 2026
JEFFREY J. KIMBELL & ASSOCIATES, INC. $10 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $10 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Gossamer Bio, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Gossamer Bio, Inc.#
2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $185 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Director, Clinical Quality AssuranceMedical and Health Services Managers | 1 | $223 K |
| Manager, Statistical ProgrammingSoftware Developers | 1 | $148 K |
Where: Billerica, MA 1 · Secaucus, NJ 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 2 | 2 | $185 K | 2 |
| FY2024 | 2 | 2 | $159 K | 2 |
| FY2023 | 1 | 1 | $165 K | 1 |
| FY2021 | 4 | 4 | $133 K | 4 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Gossamer Bio Services, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | 65 | · | · | · | · | · | · | · | · | 65 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| effective | 65 people | LayoffWARN notice | San Diego, California | Notice list |
Source: State WARN notices and SEC 8-K item 2.05
How Gossamer Bio, Inc. compares in Biotechnology
- Market cap$65 M · higher than 30% of 726
- Revenue$48 M · higher than 59% of 647
- Net margin-159.5% · higher than 34% of 408
- Revenue growth-57.7% · higher than 15% of 438
- Price / sales0.8× · lower than 95% of 339
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Gossamer Bio, Inc.🇺🇸 | $65 M | — | -159.5% | -57.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Gossamer Bio, Inc.? Verify and update this profile — free
Show Gossamer Bio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.